興科蓉醫藥(06833.HK)擬收購中山未名海濟生物醫藥100%股權
格隆匯12月6日丨興科蓉醫藥(06833.HK)公佈,2019年12月6日,公司(作為潛在買方)與潘雯女士(賣方A)、龔濤先生(賣方B)及許婕女士(賣方C)就公司可能收購中山未名海濟生物醫藥有限公司全部股權訂立不具法律約束力的諒解備忘錄。
根據備忘錄,中山未名將進行企業重組,據此,賣方將向獨立第三方收購中山未名的全部股權,而中山未名預期將由賣方A、賣方B及賣方C分別擁有60%、30%及10%權益。
中山未名為一間於中國成立的公司,其業務範圍包括基因改造產品研發、生產及銷售以及生物製品研究。
董事認為可能收購事項是拓展該集團收入基礎的機會,有助促進其生物製品分部的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.